

16 October 2003

Level 14, Cigna House,
40 Mercer Street
P O Box 10-254, Wellington
NEW ZEALAND
Phone 64 4 460 4990
Fax 64 4 460 4995

To All Interested Parties

By facsimile (1 page)

Wyeth proposal regarding venlafaxine (Efexor XR), etanercept (Enbrel) and ethinyloestradiol with levonorgestrel (Monofeme and Trifeme)

Further to the consultation letter dated 15 October 2003.

This letter stated that the listing of etanercept (Enbrel) 25 mg injection set in Section B of the Pharmaceutical Schedule would be subject to certain Special Authority criteria and restrictions that are yet to be finalised. To clarify, the special Authority criteria, which will be further developed, would be for the funding of Enbrel for Juvenile Rheumatoid Arthritis only.

It is envisaged that the Special Authority criteria would be similar to those that are currently in use for juvenile patients in Australia. PHARMAC will consult with relevant specialists over the exact wording of the Special Authority criteria before any implementation.

If you wish to make comments on this proposal, please forward them to Natalie Ganley at PHARMAC by **5 p.m. on Friday, 13 November 2003.**

Yours sincerely



Natalie Ganley
Therapeutic Group Manager